Friday, July 10, 2026

Drug profile · INN

dapagliflozin || metformin

dapagliflozin || metformin (DAPAGLIFLOZIN AND METFORMIN) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — dapagliflozin || metformin
US status
approved
Class
Route
Patents
0
Programs
3
Data quality
0.81

Quick answer

dapagliflozin || metformin (DAPAGLIFLOZIN AND METFORMIN) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

Key facts

INN dapagliflozin || metformin
Brand DAPAGLIFLOZIN AND METFORMIN
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 1019/25 Phase 1 · Tillomed Laboratories · Bioavailability study in healthy volunteers under fed condit
  2. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Phase 1 · Tillomed Laboratories · Healthy volunteers
  3. Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Phase 1 · Tillomed Laboratories · Healthy volunteers

Frequently asked questions

What is dapagliflozin || metformin?

dapagliflozin || metformin (DAPAGLIFLOZIN AND METFORMIN) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.

What is the brand name for dapagliflozin || metformin?

DAPAGLIFLOZIN AND METFORMIN is a marketed brand name for dapagliflozin || metformin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dapagliflozin || metformin?

dapagliflozin || metformin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.